This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Blotting is frequently necessary when using dip pens and occasionally when using fountain pens. This was first done by sprinkling pounce over the wet ink. When used to remove ink, the writing may appear in reverse on the surface of the blotting paper, a phenomenon which has been used as a plot device in a number of detective stories, such as in the Sherlock Holmes story "The Adventure of the Missing Three-Quarter".
== Industrial functionality == A number of halogenated compounds are environmentally toxic industrial by-products, and it has been suggested that haloalkane dehalogenases may be useful catalysts for their biodegradation, with potential applications in bioremediation. In biocatalysis, there is a standing interest in these enzymes, particularly for the production of optically pure alcohols. Therefore, the identification of dehalogenating enzymes with appropriate selectivity patterns is very important in terms of their industrial utility.
Vaccination campaigns began in Porto Alegre on 20 January 2021. Starting in January, the municipal government began to not keep second doses of the vaccine, immediately using up all of the supplies that they received from the Programa Nacional de Imunizações (PNI). This created delays in second doses by the end of April and the beginning of May, when there was a further delay in the sending out of doses of CoronaVac throughout Brazil. Long lines formed as a result of people waiting for the vaccine, but there were not enough doses to go around, implying that there were people who were immunized during a period longer than the four weeks recommended by the manufacturers. Melo recorded a video, which was released on social media, apologizing to the populace for the delays and claiming that the Ministry of Health was responsible for the error. Upon receiving the supplies of the Pfizer/BioNTech vaccine, the municipal government decided to keep the shots to be able to give a second dose, to avoid the same issue that occurred with the CoronaVac vaccines. In March, the Consortium of the Association of Municipalities of the Porto Alegre Metropolitan Region (Granpal), integrated by Porto Alegre's city government, made a proposal to buy doses of the Sputnik V vaccine that would be meant for, by law, the PNI. The purchase, however, did not go forward.
State law allows for the dispensing of the drugs/chemicals for lethal injection to the state's department of corrections without a prescription. However, states are still subject to DEA regulation with respect to lethal injection drugs.
The production of sparkling cider requires a second round of fermentation, and a second yeast selection. The yeast used for the secondary fermentation in sparkling cider production serve the same purpose as the yeast used in the champagne method of sparkling wine production: to generate carbonation and distinct aromas with a fermentation that occurs in the bottle. The yeast is selected based on critical properties, such as tolerance to high pressure, low temperature, and high ethanol concentration, as well as an ability to flocculate, which allows for riddling to remove the yeast when the fermentation has finished. Some researchers have also suggested that non-Saccharomyces yeasts could be used to release additional flavour or mouthfeel compounds, as they may contain enzymes, such as β-glucosidase, β-xylosidase, or polygalacturonase, which Saccharomyces yeast may not produce. Not all yeast associated with cider production are necessary for fermentation; many are considered spoilage microbes and can be a significant source of off odors in the finished product. Brettanomyces species produce volatile phenols, especially 4-ethyl phenol, which impart a distinct aroma called "Bretty", typically described as "barnyard", "horsey", or "bandaid". While these aromas would be considered spoilage odors in wines, many cider producers and consumers do not consider them a fault.
Sources: en.wikipedia.org
The developed structure of the aliphatic fragment promotes the formation of different conformers, thereby opening the potential for creating new solid forms with enhanced characteristics. For example, the bicalutamide solvate with DMSO demonstrated a concentration increase of up to 3.3 times compared to form I. A similar trend is observed for the metastable form II and the amorphous state, with concentrations of approximately 3.0 × 10−7 and 3.3 × 10−7 m.f., respectively, which are more than twice those of the stable form I.
=== Chemical synthesis === Synthetic taurine is obtained by the ammonolysis of isethionic acid (2-hydroxyethanesulfonic acid), which in turn is obtained from the reaction of ethylene oxide with aqueous sodium bisulfite. A direct approach involves the reaction of aziridine with sulfurous acid. In 1993, about 5000–6000 tonnes of taurine were produced for commercial purposes: 50% for pet food and 50% in pharmaceutical applications. In the laboratory, taurine can be produced by alkylation of ammonia with bromoethanesulfonate salts. Taurine can be synthesized in the laboratory from aziridines through a ring-opening reaction. The synthesis of taurine in the lab has been patented.
The role of Iraq's Scud missiles featured prominently in the war. Scud is a tactical ballistic missile that the Soviet Union developed and deployed among the forward deployed Soviet Army divisions in East Germany. Scud missiles utilize inertial guidance which operates for the duration that the engines operate. Iraq used Scud missiles, launching them into both Saudi Arabia and Israel. Some missiles caused extensive casualties, while others caused little damage. The US Patriot missile was used in combat for the first time. The US military claimed a high effectiveness against Scuds at the time, but later analysis gives figures as low as 9%, with 45% of the 158 Patriot launches being against debris or false targets. The Dutch Ministry of Defense, which also sent Patriot missiles to protect civilians in Israel and Turkey, later disputed the higher claim. There is at least one incident of a software error causing a Patriot missile's failure to engage an incoming Scud, resulting in deaths. Both the US Army and the missile manufacturers maintained the Patriot delivered a "miracle performance" in the Gulf War.
=== Tau in Frontotemporal Lobar Degeneration (FTLD) === The tau protein is one of the most common aggregated proteins in frontotemporal lobar degeneration (FTLD), the pathology underlying FTD disorders, the other being TDP-43. While protein aggregation underlies FTLD tauopathies, the specific tau isoforms present and the morphology of the aggregates vary across subtypes. FTLD tauopathies are predominantly associated with the 3R and 4R tau isoforms. The “Pick bodies” characteristic of the FTLD tauopathy known as “Pick’s disease” is associated with 3R tau. Progressive supranuclear palsy (PSP) and corticobasal syndrome/degeneration (CBS/CBD), meanwhile, are associated with the 4R isoform. There is evidence that a ratio of 3R and 4R tau is essential for preventing neurodegeneration, and that alterations in this ratio are believed to drive FTLD and related disorders without requiring co-occurrence with other pathologies. FTD-tau appears to be sporadic in the majority of people diagnosed, but researchers do not yet fully understand the pathological mechanisms. Inherited pathogenic variants in the MAPT gene, however, are responsible for a fraction of people diagnosed with FTD-tau. Within and between families, FTD due to MAPT presents with significant heterogeneity in the symptoms that may be present, underscoring the possibility for genetic modifiers and environmental factors to influence clinical presentation. Intronic variants in MAPT, and most variants in exon 10, affect the 3R/4R tau ratio, contributing significantly to the development of FTLD pathology.
=== Violence towards voters === On October 30, 2024, an 18-year-old man in Jacksonville, Florida, was arrested for aggravated assault and improper exhibition of a dangerous weapon after brandishing a machete at two women outside an early voting center. He, along with seven other teenagers, allegedly approached and antagonized members of the opposing political party as they were demonstrating. Neither the teenager's nor the women's political parties were disclosed, although later posts by the Duval Democratic Party described the teenager's party as a "group of young men carrying Trump flags". On November 1, 2024, a voter wearing a "Let's Go Brandon" hat was reportedly struck by a poll worker after a verbal altercation over his hat at an Orangeburg County, South Carolina, polling location. Also on November 1, a man in Bath, New York, was arrested for assaulting someone in a supermarket for wearing a Trump hat.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.